George Follows

机构：Addenbrooke's Hospital · ORCID：0000-0002-8489-0762

发表论文 220 篇 · 总被引 10989 次 · h-index 44

代表论文

• Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial (2023 · The Lancet Oncology · 被引 147)
• Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN (2025 · Blood · 被引 44)
• Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor–Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321) (2025 · Journal of Clinical Oncology · 被引 39)
• The long-term effects of chemotherapy on normal blood cells (2025 · Nature Genetics · 被引 37)
• Telomere attrition becomes an instrument for clonal selection in aging hematopoiesis and leukemogenesis (2025 · Nature Genetics · 被引 23)
• BRUIN CLL-321: Randomized Phase III Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab (IdelaR) or Bendamustine Plus Rituximab (BR) in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (2024 · Blood · 被引 20)